US Stock MarketDetailed Quotes
NGNE Neurogene
- 34.130
- -1.850-5.14%
Close Jul 5 16:00 ET
- 35.020
- +0.890+2.61%
Post 18:21 ET
443.02MMarket Cap-12051P/E (TTM)
35.865High33.670Low69.48KVolume35.780Open35.980Pre Close2.38MTurnover1.17%Turnover RatioLossP/E (Static)12.98MShares53.00052wk High2.59P/B203.11MFloat Cap12.20052wk Low--Dividend TTM5.95MShs Float1115.000Historical High--Div YieldTTM6.10%Amplitude7.500Historical Low34.300Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Neurogene Stock Forum
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet